Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APREGet Rating) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 885,700 shares, a decrease of 9.0% from the October 15th total of 973,700 shares. Based on an average daily volume of 122,400 shares, the days-to-cover ratio is currently 7.2 days. Approximately 4.5% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Aprea Therapeutics in a research note on Monday, October 10th.

Hedge Funds Weigh In On Aprea Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in APRE. Jane Street Group LLC bought a new position in Aprea Therapeutics during the second quarter worth $54,000. BNP Paribas Arbitrage SNC acquired a new position in Aprea Therapeutics in the third quarter valued at approximately $40,000. Gyon Technologies Capital Management LP acquired a new stake in shares of Aprea Therapeutics during the 1st quarter worth approximately $38,000. Finally, Renaissance Technologies LLC grew its holdings in Aprea Therapeutics by 5.7% in the first quarter. Renaissance Technologies LLC now owns 297,900 shares of the company’s stock worth $554,000 after purchasing an additional 15,977 shares during the period. 18.95% of the stock is owned by institutional investors and hedge funds.

Aprea Therapeutics Stock Performance

Shares of NASDAQ APRE opened at $0.38 on Friday. The firm has a 50 day moving average price of $0.68 and a two-hundred day moving average price of $0.83. The stock has a market cap of $7.95 million, a P/E ratio of -0.07 and a beta of 0.74. Aprea Therapeutics has a 52-week low of $0.33 and a 52-week high of $4.70.

About Aprea Therapeutics

(Get Rating)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.

Featured Articles

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.